Medicare Rx Marketing Materials Will Get Expedited Approval
This article was originally published in The Pink Sheet Daily
CMS expands “file and use” policy to allow plans to certify that material is in compliance. Certification process will “level playing field” for new part D plans. The agency will announce a “litany” of materials that will qualify for accelerated process.
You may also be interested in...
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts